Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Arteries of the Lower Limbs01:24

Arteries of the Lower Limbs

188
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
188
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

382
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
382
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

176
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
176
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

288
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
288
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

388
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
388
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

522
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
522

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Is Cardiovascular Mortality Among People with Epilepsy increasing? A retrospective US population study.

BMJ open·2025
Same author

Oxygen-15 Labeled Water Positron Emission Tomography During External Trigeminal Nerve Stimulation.

Neuromodulation : journal of the International Neuromodulation Society·2025
Same author

Mood and Anxiety Disorders and Suicidality in Patients With Newly Diagnosed Focal Epilepsy: An Analysis of a Complex Comorbidity.

Neurology·2025
Same author

Antiseizure medications and their differing effects on cardiovascular risk.

Epilepsy & behavior reports·2025
Same author

Long-Term Seizure Outcome With or Without Vagal Nerve Stimulation Therapy.

Neurology. Clinical practice·2024
Same author

Should neurologists initiate treatment for hypertension and hyperlipidemia to reduce cardiovascular risk in epilepsy?

Frontiers in neurology·2024

Related Experiment Video

Updated: Jun 28, 2025

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
08:28

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

17.8K

Increased cardiovascular risk in epilepsy.

Mark L Gaertner1,2, Scott Mintzer3, Christopher M DeGiorgio1,2

  • 1Department of Neurology, David Geffen-UCLA School of Medicine, Los Angeles, CA, United States.

Frontiers in Neurology
|April 18, 2024
PubMed
Summary
This summary is machine-generated.

People with epilepsy face higher mortality risks, largely due to cardiovascular disease. Managing epilepsy and its associated cardiovascular risks, like hyperlipidemia, is crucial for improving patient outcomes.

Keywords:
anti seizure drugscardiovascular risk (CV risk)epilepsyepilepsy mortalitysudden unexpected death in epilepsy (SUDEP)

More Related Videos

Simultaneous Video-EEG-ECG Monitoring to Identify Neurocardiac Dysfunction in Mouse Models of Epilepsy
11:54

Simultaneous Video-EEG-ECG Monitoring to Identify Neurocardiac Dysfunction in Mouse Models of Epilepsy

Published on: January 29, 2018

25.5K
Multi-system Monitoring for Identification of Seizures, Arrhythmias and Apnea in Conscious Restrained Rabbits
10:25

Multi-system Monitoring for Identification of Seizures, Arrhythmias and Apnea in Conscious Restrained Rabbits

Published on: March 27, 2021

6.0K

Related Experiment Videos

Last Updated: Jun 28, 2025

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
08:28

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

17.8K
Simultaneous Video-EEG-ECG Monitoring to Identify Neurocardiac Dysfunction in Mouse Models of Epilepsy
11:54

Simultaneous Video-EEG-ECG Monitoring to Identify Neurocardiac Dysfunction in Mouse Models of Epilepsy

Published on: January 29, 2018

25.5K
Multi-system Monitoring for Identification of Seizures, Arrhythmias and Apnea in Conscious Restrained Rabbits
10:25

Multi-system Monitoring for Identification of Seizures, Arrhythmias and Apnea in Conscious Restrained Rabbits

Published on: March 27, 2021

6.0K

Area of Science:

  • Neurology
  • Cardiology
  • Public Health

Background:

  • Epilepsy is linked to increased mortality, with cardiovascular disease being a major contributor.
  • There is growing recognition of the cardiovascular mortality burden in individuals with epilepsy.
  • Common cardiovascular risk factors such as obesity, diabetes mellitus, and hyperlipidemia are frequently associated with epilepsy.

Purpose of the Study:

  • To review common cardiovascular risk factors in epilepsy patients.
  • To discuss the association between epilepsy and cardiovascular disease.
  • To highlight the role of neurologists in managing cardiovascular risk in epilepsy.

Main Methods:

  • Literature review of studies examining cardiovascular risk factors in epilepsy.
  • Discussion of hyperlipidemia associated with enzyme-inducing anti-seizure medications.
  • Exploration of heart rate variability (HRV) and its link to Sudden Unexpected Death in Epilepsy (SUDEP) and vascular risk.

Main Results:

  • Obesity, diabetes mellitus, and hyperlipidemia are prevalent in epilepsy populations.
  • Enzyme-inducing anti-seizure medications can exacerbate hyperlipidemia.
  • Reduced heart rate variability (HRV) is associated with SUDEP and may indicate increased vascular risk.

Conclusions:

  • Neurologists play a vital role in assessing and managing cardiovascular risk factors in epilepsy patients.
  • Utilizing tools like the ASCVD score calculator can help determine overall mortality risk.
  • Integrating cardiovascular risk management into epilepsy treatment plans is essential for reducing mortality.